Changing paradigms in dermatology: topical immunomodulators within a permutational paradigm for the treatment of atopic and eczematous dermatitis

The first formulation of a class of products called topical immuno modulator s (TIMS) was approved for clinical use in December 2000 and released in February 2001. This product is tacrolimus in an ointment base, prescribed under the trademark Protopic™. The next TIM, pimecrolimus cream, was FDA appr...

Full description

Saved in:
Bibliographic Details
Published in:Clinics in dermatology 2003-09, Vol.21 (5), p.383-391
Main Authors: Abramovits, William, Goldstein, Adrian M., Stevenson, Lisa C.
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - administration & dosage
Administration, Topical
Allergic diseases
Biological and medical sciences
Dermatitis, Atopic - drug therapy
Dermatitis, Atopic - immunology
Dermatology
Dermatology - methods
Dermatology - trends
Eczema - drug therapy
Eczema - immunology
Humans
Immunopathology
Medical sciences
Skin allergic diseases. Stinging insect allergies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The first formulation of a class of products called topical immuno modulator s (TIMS) was approved for clinical use in December 2000 and released in February 2001. This product is tacrolimus in an ointment base, prescribed under the trademark Protopic™. The next TIM, pimecrolimus cream, was FDA approved in December 2001 and launched February 2002 in a cream vehicle under the trademark Elidel®. TIMs are becoming a significant component in the topical treatment paradigm for atopic dermatitis, introducing a useful alternative to, or complement for, high- and low-potency topical steroid therapy.
ISSN:0738-081X
1879-1131
DOI:10.1016/j.clindermatol.2003.08.013